This article is more than 5 years old. Information may no longer be current.
JAK inhibitor yields hair growth in women: Top dermatology stories from last week
Click Here to Manage Email Alerts
In the top Healio Dermatology story from last week, inflammation plays a key role in male and female pattern hair loss, according to a phase 2, open-label clinical trial in patients with androgenetic alopecia.
“Looking at the aggregate of the data, any way you looked at it was positive. If you look at target area hair count, the physicians’ global assessment or the subjects’ assessment, they all showed nice results,” said Neal Walker, DO, president and CEO of Aclaris Therapeutics.
In other big news from last week, approximately half of patients with vitiligo treated with ruxolitinib cream achieved a 50% improvement in facial Vitiligo Area Severity Index scores at week 24, meeting the primary endpoint in a phase 2 study. David Rosmarin, MD, primary investigator of the study, explained the study results an interview. Click through below to read more.
JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia
ATI-502, an investigational topical JAK 1/3 inhibitor, was evaluated in adult women and men with androgenetic alopecia and applied to the scalp twice daily for 26 weeks. Read more.
Results ‘promising’ in phase 2 study of ruxolitinib cream for patients with vitiligo
Approximately half of patients with vitiligo treated with ruxolitinib cream achieved a 50% improvement in facial Vitiligo Area Severity Index scores at week 24, meeting the primary endpoint in a phase 2 study, David Rosmarin, MD, primary investigator of the study, told Healio Dermatology. Read more.
Hidradenitis suppurativa increases risk for alopecia
In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa had a significantly higher risk for alopecia of any type and also lichen planopilaris. Read more.